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A systematic review was conducted to examine the
associations in Pneumocystis jirovecii pneumonia (PCP)
patients between dihydropteroate synthase (DHPS) muta-
tions and sulfa or sulfone (sulfa) prophylaxis and between
DHPS mutations and sulfa treatment outcome. Selection
criteria included study populations composed entirely of
PCP patients and mutation or treatment outcome results for
all patients, regardless of exposure status. Based on 13
studies, the risk of developing DHPS mutations is higher for
PCP patients receiving sulfa prophylaxis than for PCP
patients not receiving sulfa prophylaxis (p < 0.001). Results
are too heterogeneous (p < 0.001) to warrant a single sum-
mary effect estimate. Estimated effects are weaker after
1996 and stronger in studies that included multiple isolates
per patient. Five studies examined treatment outcome. The
effect of DHPS mutations on treatment outcome has not
been well studied, and the few studies that have been con-
ducted are inconsistent even as to the presence or
absence of an association. 
P
neumocystis  jirovecii causes pneumonia in immuno-
compromised persons, especially those with AIDS,
worldwide (1). In industrialized countries, while the inci-
dence of Pneumocystis jirovecii pneumonia (PCP) has
declined substantially since highly active antiretroviral
therapy (HAART) was introduced in 1996 (2), PCP
remains the leading serious opportunistic infection (3–5).
Not all patients treated with HAART have CD4-cell count
boosts above the range at which PCP occurs (6–9). In
developing countries, where only 7% of HIV/AIDS
patients who need therapy have access to HAART (10), the
incidence of PCP is increasing. 
Prophylaxis against PCP has been standard practice in
industrialized countries for >20 years. Trimethoprim-
sulfamethoxazole (TMP-SMX) is the first-line drug choice
for both prophylaxis and therapy. TMP-SMX acts in ani-
mals as sulfa monotherapy against the enzyme dihy-
dropteroate synthase (DHPS) (11,12). Dapsone, a sulfone
drug also targeting DHPS, is frequently used as a second-
line agent for prophylaxis and treatment of PCP.
Failure of sulfa or sulfone (sulfa) prophylaxis against
PCP has been reported in up to one fourth of patients
(13,14). To assess the role of drug resistance in these fail-
ures, investigators examined whether DHPS mutations are
more frequent among patients with or without prior expo-
sure to sulfa agents, and whether infections in patients with
or without DHPS mutations are more likely to be unre-
sponsive to a sulfa drug. These studies are hampered by
scientists’ inability to culture P. jirovecii, which prevents
direct confirmation of resistance through standard drug-
susceptibility testing. Instead, researchers use polymerase
chain reaction to detect P. jirovecii DHPS mutations that
cause sulfa resistance in other microorganisms. DHPS
mutations in P. jirovecii may also increase the incidence of
treatment failure. A systematic review can determine
whether available studies give overall evidence of an asso-
ciation, assess the possibility of publication bias, examine
results across studies for consistency, and investigate study
and patient characteristics for possible influence on study
results. 
Methods
Literature Search
MEDLINE (National Library of Medicine, Bethesda,
MD) was searched with the keywords “Pneumocystis,”
“Pneumocystis carinii,” and “drug resistance” (last
searched January 2004). ISI Web of Science (Institute for
Scientific Information, Philadelphia, PA) was searched
with the keywords “pneumocystis pneumonia,” “resist-
ance,” and “genes” (last searched January 2004). The
bibliographies of relevant articles were surveyed for
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USAadditional studies. One author (S.R.M.) contacted 42 sci-
entists through an informal PCP email forum to request
unpublished results and conference abstracts on associa-
tions between sulfa prophylaxis and Pneumocystis muta-
tions and Pneumocystis mutations and sulfa treatment
outcome.
Information Extraction
Inclusion requirements were the following: study pop-
ulations composed entirely of PCP patients; mutation
results for all patients, regardless of sulfa prophylaxis
exposure; and treatment outcome results for all patients,
regardless of mutation status. Studies reporting the out-
come (mutation status or treatment failure) only for
exposed patients (on prophylaxis or with mutations) were
not included because these studies would have biased the
analyses by not providing information on unexposed pop-
ulations for comparison. When more than one article
reported on the same study population, only the more
comprehensive article was included. From every eligible
report, one author extracted information on publication
year, study location(s), study start and end dates for cal-
culating data collection calendar midpoint, study size,
proportion of HIV-positive patients, number of isolates
per patient, timing of prophylaxis in relation to PCP, treat-
ment outcome definition, number and type of DHPS
mutations in patients receiving or not receiving sulfa pro-
phylaxis, and sulfa treatment outcome among patients
with and without DHPS mutations. Multiple isolates from
the same patient were included as independent counts of
PCP.
Statistical Analysis 
STATA Version 8.2 (Stata Corp., College Station, TX)
was used to analyze estimates of the effect of prophylaxis
on mutation occurrence and estimates of the effect of
mutation on treatment outcome. Both analyses used the
risk difference (RD) as the effect measure. Qualitatively
similar results were obtained by using the risk ratio and
incidence odds ratio (15). The number of patients needed
to treat (NNT) to increase or decrease the number of out-
comes by one may be computed as NNT = RD–1 (16). The
95% confidence limit difference (CLD), computed as the
difference between the upper and lower limits of the 95%
confidence interval (CI), was used to gauge the precision
of the study-specific RD estimates, with smaller values
denoting more precise estimates (17). We obtained p val-
ues for overall association from the meta-analysis of RD
estimates by means of the Mantel-Haenszel test statistic.
The potential for publication bias was assessed by visually
examining funnel plots of RD estimates and by using stan-
dard tests of funnel plot asymmetry (18,19). Homogeneity
test statistics and their associated p values were computed
to assess the consistency of estimated RDs across studies.
Random-effects meta-regression and stratified analyses
were used to estimate associations between RD estimates
and characteristics of studies and patients. The precision-
weighted meta-regression models incorporated random
effects by using a restricted maximum likelihood method
to estimate the among-study variance (20). 
Results
Thirteen eligible studies were identified for the analysis
of the effect of prophylaxis on mutation (21–33) and five
for the analysis of mutation effect on treatment outcome
(Table 1) (25–27,34,35). Three studies were included in
both analyses (25–27). 
Prophylaxis Effect on Mutation
In this analysis, the estimated RD from each study is
the risk of developing a DHPS mutation among PCP
patients exposed to sulfa prophylaxis minus the risk among
PCP patients not exposed to sulfa prophylaxis. The RD
meta-analysis produced strong evidence of a positive asso-
ciation (p < 0.001). Twelve of the 13 studies reported
results suggesting that prophylaxis increases the risk for
DHPS mutations, and 95% CI of 10 of the 13 excluded the
null value (Table 1, Figure). The 12 positive RD estimates
ranged from a 10% increase in risk (28) to a 69% increase
(23). The least precise estimate came from a study with
only 20 isolates (26), and the most precise estimate from a
study with 236 (29). Visual inspection of the funnel plot,
Begg and Mazumdar’s test (p = 0.5), and the test of Egger
et al. (p = 0.1) all gave no appreciable evidence of asym-
metry. The study-specific results were highly heteroge-
neous (p < 0.001), however. As shown in the Figure, the
95% CI for three estimates (27,29,30) did not overlap the
CI for five other estimates (22,23,25,32,33). No single
summary estimate can adequately describe results as dis-
parate as these (36).
Of the examined characteristics, data collection calen-
dar midpoint and multiple isolates both had strong associ-
ations with the study results (Table 2). Higher estimated
RDs were produced by studies in which at least half of the
data was collected before 1996 (21–23,25,26,31,32) and
from studies including multiple isolates per patients
(22,23,26,29,33). Three studies had a data collection cal-
endar midpoint before 1996 and used multiple isolates per
patient (22,23,26). The magnitude of the combined influ-
ence of these two characteristics on the estimate (differ-
ence of RD = 0.10, 95% CLD 0.22) was less than either of
the individual characteristics examined singly. Only two
studies with a midpoint of 1996 or later included multiple
isolates from the same patient (27,28).
The four studies that detailed prophylactic drug use for
each specific mutation had a high homogeneity p value (p
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One study did not provide information on the timing of
sulfa prophylaxis in relation to the PCP episode (26). With
this study removed so its influence on the meta-analysis
could be evaluated, the homogeneity p value remained low
for the other 12 studies (p < 0.001). The remaining charac-
teristics were weakly associated with study results. 
Mutation Effect on Treatment Outcome
In this analysis, the estimated RD from each study is
the risk of failing sulfa treatment for PCP among patients
with DHPS mutations minus the risk among patients with-
out DHPS mutations. Five studies provided such a result.
One of these studies had a mixed HIV-positive and HIV-
negative patient population (34), and another did not
describe the criteria for determining treatment outcome
(26). Three of the studies included in the analysis of pro-
phylaxis effect on mutation (22,30,32) mentioned examin-
ing treatment outcome but did not provide usable treatment
outcome data for the full study population. 
Assessing publication bias was impractical with only
five published studies. Two of the five suggested that
patients infected with mutant P. jirovecii were unexpected-
ly more likely to be responsive to treatment for PCP (Table
1) (26,35). One study showed that mutations had virtually
no effect (27). The remaining two studies were on the
opposite side of the null hypothesis (Table 1) (25,34). The
pronounced evidence of heterogeneity (p < 0.001) was eas-
ily discerned by examining CI nonoverlap, since the 95%
CI for the study with the highest estimate for increased
risk(34) did not overlap any of the other four CIs.
Discussion
PCP patients receiving sulfa prophylaxis are at
increased risk for DHPS mutations compared with PCP
patients not receiving sulfa. The strength of the association
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Not all studies adhered to a uniform definition of sub-
stantive sulfa exposure. Only some defined a minimum
duration of prophylaxis use, often in conjunction with the
timing of the PCP episode, for a patient to be counted as
receiving prophylaxis. Some studies were more compre-
hensive in documenting prophylactic drug use by pulling
pharmacy records to verify that prophylactic medications
were dispensed or patient questionnaires to confirm that
the drug was taken. Moreover, the association between
prophylactic drug use and mutation was stronger for the
studies that included multiple isolates than for those that
did not. This difference suggests the possibility that expo-
sure to multiple courses of sulfa prophylaxis increases the
chance of developing DHPS mutations. The weakened
association evident since 1996 may reflect a higher overall
prevalence of mutation with a higher prevalence among
those unexposed to prophylaxis, or it may reflect that
fewer HIV-infected patients take prophylactic drugs
because of HAART. Each of these factors may bear on the
strength of the association between sulfa prophylaxis and
DHPS mutations. Variations in unreported aspects of study
design or patient characteristics may account for the
remaining inconsistency in estimated effect size. 
One of the 13 studies reported an inverse association
between prophylaxis and mutations (30). Unlike the other
studies, this study categorized prophylaxis use as regular,
irregular, none, and unknown. We categorized sulfa expo-
sure as regular or irregular use. Had we counted only reg-
ular prophylactic drug use as sulfa exposure, the
association in this study would have been positive, albeit
very imprecise (RD = 0.17, 95% CLD = 1.32).
Additionally, the isolates in this study were collected more
recently than in other studies, with all specimens collected
after 1998.
This systematic review was unable to resolve the con-
flicting results regarding the magnitude of the effect of
DHPS mutations on treatment outcome. Only five studies
were eligible for inclusion in this analysis. Although the
small number of studies precluded a statistical investiga-
tion of possible explanations for the inconsistent findings,
variation in definitions of treatment outcome may be par-
tially responsible. The two studies with positive associa-
tions used clinical improvement after therapy to determine
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Figure. Forest plot, prophylaxis effect on mutation. CI, confidence
intervals.treatment outcome (25,34), whereas the two studies with
negative associations defined treatment outcome as sur-
vival after the episode (26,35). The treatment outcome def-
inition for the study showing minimal effect used both
survival and clinical recovery without relapse (27). HIV
status may also have swayed the results. The sole study to
include HIV-uninfected patients noted the strongest asso-
ciation between mutation and treatment outcome (34).
This systematic review has both strengths and limita-
tions. It included information on all relevant studies for
which results have been reported, examined how different
study characteristics influenced the magnitude of effect
estimates, and provided information that may be useful
when designing future studies of a similar nature. Its prin-
cipal weakness was that the small number of available
studies, especially for treatment outcome, made the results
from stratified analysis and meta-regression less precise
than would be desirable.
We conclude that exposure to sulfa prophylaxis for PCP
increases the risk for DHPS mutations. This finding is evi-
dent even with the heterogeneity of the individual study
results. Although whether these mutations are clinically
relevant is unclear, they are likely to develop in patients
who have received sulfa prophylaxis for PCP for extended
periods. This review did not clarify the effect of these
mutations on treatment outcome. Further studies are need-
ed to examine the association between DHPS mutations
and treatment outcome in patients with PCP. Until these
studies are performed, the optimal treatment for patients
with PCP, who have had substantive exposure to sulfa pro-
phylaxis and who are therefore likely to have DHPS muta-
tions, remains speculative.
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